Eli Lilly raises annual forecasts as new diabetes drug powers beat

Eli Lilly on Tuesday raised its annual forecasts after beating estimates for quarterly profit, driven by strong demand for its new diabetes drug Mounjaro, ahead of a decision on its use as a weight-loss treatment. The company is leaning on Mounjaro, approved last May in the U.S. for diabetes, to…

#elililly #mounjaro #alimta #novonordisk #obese #lilly